CJC-1295 No DAC 5mg + Ipamorelin 5mg
CJC-1295 No DAC 5mg + Ipamorelin 5mg
For research use only. Not for human or animal consumption.
CJC-1295 No DAC + Ipamorelin – 10mg Research Blend
CJC-1295 No DAC + Ipamorelin is a dual-peptide research blend designed for laboratory investigation into growth hormone signalling pathways, recovery mechanisms, and metabolic regulation.
This formulation combines:
- 5mg CJC-1295 No DAC (MOD GRF 1-29)
- 5mg Ipamorelin
Both peptides are widely studied in preclinical environments due to their complementary interaction with endogenous growth hormone release pathways.
CJC-1295 No DAC acts as a modified Growth Hormone Releasing Hormone (GHRH) analogue, while Ipamorelin functions as a selective Growth Hormone Secretagogue Receptor (GHSR) agonist. Together, they are commonly researched for their synergistic signalling properties and controlled pulsatile GH release patterns.
Product Highlights
- Dual peptide blend containing 5mg + 5mg
- Research-focused GH signalling support
- Frequently studied in recovery and metabolic models
- High purity lyophilised peptide formulation
- Batch-tested with analytical verification
- Designed for controlled laboratory research applications
Research Overview
In experimental settings, CJC-1295 No DAC + Ipamorelin is commonly investigated for its role in:
- Growth hormone signalling dynamics
- peptide-mediated receptor interactions
- Recovery and regeneration models
- Sleep and recovery pathway research
- Metabolic and fat oxidation studies
- Cellular signalling and endocrine response analysis
Researchers value this combination because both compounds stimulate GH release through different mechanisms while maintaining a controlled and balanced response profile.
Mechanism of Action
CJC-1295 No DAC
CJC-1295 No DAC is a shortened GHRH analogue engineered to stimulate natural pulsatile growth hormone release. Unlike DAC-modified versions, it has a shorter half-life, allowing more precise timing and controlled research protocols.
Ipamorelin
Ipamorelin is a selective ghrelin receptor agonist studied for its ability to stimulate GH secretion with minimal interaction with cortisol and prolactin pathways.
Combined Research Interest
The combination is frequently explored in peptide research models investigating:
- GH pulse amplification
- Recovery signalling
- peptide synergy
- Endocrine pathway modulation
- Controlled peptide-release dynamics
Purity & Quality
Each batch undergoes independent analytical testing to verify:
- peptide identity
- High purity standards
- Sterility controls
- Batch consistency
- Research-grade quality assurance
COA documentation is available with each batch where applicable.
Storage & Handling
- Supplied as a lyophilised powder
- Store refrigerated at 2–8°C after reconstitution
- Intended for controlled laboratory handling only
- Reconstitute using appropriate laboratory-grade bacteriostatic solution
Package Contents
- 1 × Research vial containing:
- 5mg CJC-1295 No DAC
- 5mg Ipamorelin
Total peptide content: 10mg
Important Disclaimer
This product is intended strictly for laboratory and scientific research purposes.
- Not for human consumption
- Not for medical, cosmetic, or veterinary use
- Not intended to diagnose, treat, research, or prevent disease
- Purchase only if qualified to handle compounds
Why Researchers Choose This Blend
CJC-1295 No DAC + Ipamorelin remains one of the most researched peptide combinations due to its balanced signalling profile and compatibility with controlled GH pulse studies.
The short-acting nature of both peptides allows researchers to investigate timing-dependent hormone release patterns while maintaining flexible experimental protocols.
TEST RESULTS
What our customers say
Independent customer feedback from Trustpilot

